The role of vasodilator therapy in the treatment of severe chronic heart failure
- PMID: 3552590
- DOI: 10.2165/00003495-198600325-00003
The role of vasodilator therapy in the treatment of severe chronic heart failure
Abstract
The rationale for the use of vasodilating agents in the treatment of congestive heart failure is to reverse the systemic vasoconstriction that characterises patients with this disorder, and which may further limit cardiac performance. Nitrates were the first vasodilators used, followed by arterial vasodilators (hydralazine, minoxidil), alpha-adrenergic blockers (prazosin, trimazosin) and, more recently, calcium antagonists, ACE inhibitors, beta-agonists and phosphodiesterase inhibitors. The choice of vasodilator should be based on consideration of overall benefit-risk profiles. Consideration of pharmacological action together with classification of patients into haemodynamic subsets has been used as a basis from which to initiate vasodilator therapy. However, such a classification may not lead to a logical choice of drug and there is no evidence to suggest that patients so selected do better when given long term treatment with peripherally specific drugs than with agents that are not tailored to pretreatment haemodynamic variables. Moreover, changes in central haemodynamics after administration of specific vasodilator drugs may differ from those expected on the basis of their presumed actions on the peripheral vasculature. Dosage requirements are difficult to predict with many vasodilator drugs. Traditionally, such requirements have been established by titrating vasodilating drugs to achieve an arbitrarily defined haemodynamic response. However, there is little correlation between haemodynamic end-points and clinical efficacy in patients with heart failure, and short and long term haemodynamic responses to vasodilator drugs are not necessarily related. Drug-specific haemodynamic and clinical tolerance occurs during the course of treatment with all vasodilator drugs; the extent and frequency with which it develops differs between agents. Tolerance is thought to arise from a reduction in drug receptor affinity and/or density or activation of counter-regulatory forces (mainly neurohormonal) that limit the magnitude of vasodilatation that can be achieved. Development of tolerance to a single agent does not usually preclude efficacy of other agents. ACE inhibitors have been associated with a relatively low incidence of tolerance. This may relate to their natriuretic effect and ability to decrease the degree of neurohormonal activation, actions not shared by other vasodilators. Tolerance is the principal reason for failure of prazosin and nitrates as therapeutic agents in severe chronic heart failure.(ABSTRACT TRUNCATED AT 400 WORDS)
Similar articles
-
Vasodilator therapy in chronic congestive heart failure.Drugs. 1983 Aug;26(2):148-73. doi: 10.2165/00003495-198326020-00003. Drugs. 1983. PMID: 6349967 Review.
-
[The extension of heart failure therapy with vasodilators].Z Gesamte Inn Med. 1990 Jun 15;45(12):352-6. Z Gesamte Inn Med. 1990. PMID: 2201132 Review. German.
-
[Vasodilator agents in chronic heart failure: which is the best option?].Rev Med Chil. 1993 Jan;121(1):81-8. Rev Med Chil. 1993. PMID: 8235172 Review. Spanish.
-
Aspects on "traditional" vasodilators in the treatment of chronic heart failure.Acta Med Scand Suppl. 1986;707:85-90. doi: 10.1111/j.0954-6820.1986.tb18121.x. Acta Med Scand Suppl. 1986. PMID: 3526822 Clinical Trial.
-
Selection of vasodilator drugs for patients with severe chronic heart failure: an approach based on a new classification.Drugs. 1982 Jul;24(1):64-74. doi: 10.2165/00003495-198224010-00003. Drugs. 1982. PMID: 6125370 Review.
Cited by
-
Centrally acting sympatholytic agents in the treatment of congestive heart failure. A review of the literature.Drugs. 1990 Aug;40(2):169-75. doi: 10.2165/00003495-199040020-00001. Drugs. 1990. PMID: 2226211 Review. No abstract available.
-
Angiotensin converting enzyme inhibitors.Br Med J (Clin Res Ed). 1988 Feb 27;296(6622):618-20. doi: 10.1136/bmj.296.6622.618. Br Med J (Clin Res Ed). 1988. PMID: 2832034 Free PMC article. Review. No abstract available.
-
ACE inhibitors and anaesthesia.Postgrad Med J. 1989 May;65(763):273-4. doi: 10.1136/pgmj.65.763.273. Postgrad Med J. 1989. PMID: 2692007 Free PMC article. Review. No abstract available.
-
The place of ACE inhibitors in the current treatment of chronic heart failure.Postgrad Med J. 1988 Sep;64(755):653-5. doi: 10.1136/pgmj.64.755.653. Postgrad Med J. 1988. PMID: 3075041 Free PMC article. Review. No abstract available.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous